WESTLAKE-CORPORATION
11.7.2024 21:17:27 CEST | Business Wire | Press release
This year, a particularly large number of plastics converters took part in the annual polymer producers’ assessment sponsored by the Polymers for Europe Alliance. All polymers users in Europe had until mid-May to vote and rate their polymer suppliers' performance during the past 12 months. Following this year's key criteria delivery reliability, circularity, quality, communication, innovation and commitment to the European Market, Westlake Vinnolit won the PVC category with 92% of the vote. "We are delighted with this great success and would like to thank our customers for their continued trust and inspiration," said Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia, and Managing Director of Westlake Vinnolit. "At the same time, this is the greatest incentive for us to continue to improve."
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240711680182/en/
‘Supplier of the year for PVC’ and ‘Overall Award – Decarbonisation’ for Westlake Vinnolit: Ron Marsh, Chairman of the Polymers for Europe Alliance (left), congratulated Dr. Karl-Martin Schellerer, Senior Vice President, Westlake Performance and Essential Materials - Europe and Asia. (Photo: Polymers for Europe Alliance)
Furthermore, Westlake Vinnolit also won the ‘Overall Award – Decarbonization.’ “The PVC Award is a major accolade, surpassed only by being awarded the number one plastics supplier in terms of decarbonization,” said Schellerer, who received the awards and certificates from Ron Marsh, Chairman of the Alliance, and EuPC President Benoît Hennaut, at the ceremony that took place at the European Plastics Converters’ conference ‘A Circular Future with Plastics’ in Brussels. “The de-fossilization of plastics is an important building block in the effort to combat climate change and one of the biggest challenges for the industry. With our CO2-saving GreenVin® product line, we actively support our customers in helping them to reduce Scope 3.1 emissions and advance their sustainability goals.”
Vinnolit GreenVin® PVC is produced entirely with electricity from renewable energy sources, backed with European high-quality certificates for renewable energies (Guarantees of Origin / HKNs) and saves around 25% CO2 equivalents in comparison to conventionally produced ®Vinnolit PVC. The respective carbon footprint was calculated by Sustainable AG in accordance with the ISO 14067 standard and certified by TÜV Rheinland. GreenVin® bio-attributed PVC, in addition, uses renewable ethylene based on 2nd generation biomass, which increases the CO2 savings to around 90%, taking into account the biogenic CO2 fixation. Vinnolit GreenVin® bio-attributed PVC is mass-balanced and certified according to ISCC PLUS and REDcert2. The favorable product and processing properties desired by customers remain unchanged.
The Polymers for Europe Alliance was initiated by the European Plastics Converters association (EuPC) to provide factual public information on the status of the polymer supply situation in Europe and to engage in a constructive dialogue with the supply base. The initiatives of the Alliance also include the Polymer Producers Awards for Europe. In this Europe-wide customers’ satisfaction survey all users of polymers in Europe can rate their suppliers of the year.
ABOUT WESTLAKE VINNOLIT
As a leading manufacturer for PVC and an important partner for caustic soda, Westlake Vinnolit offers individual solutions for customers from a wide range of industries, such as the construction sector, the automotive industry, medical technology or pulp and paper production. As a manufacturer of high-quality PVC specialties, Westlake Vinnolit is a global market leader. At its headquarters in Ismaning near Munich and its four production sites in Burghausen, Gendorf, Knapsack and Cologne, 1,400 employees generate annual sales of more than €1 billion.
Westlake Vinnolit participates in the chemical industry's Responsible Care program for the continuous improvement of safety, health and environmental protection and supports VinylPlus®, the European PVC industry's voluntary commitment to sustainable development, as an "Official Partner" financially, ideally and through active participation. For more information visit www.westlakevinnolit.com
ABOUT WESTLAKE CORPORATION (WLK)
Westlake is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the Company's web site at www.westlake.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711680182/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
